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ABSTRACT
Recently, modified REACH-B (mREACH-B) risk prediction model for hepatocellular 
carcinoma (HCC) development was proposed. We validated the accuracy of the 
mREACH-B model and compared its accuracy with those of other prediction models. 
Between 2006 and 2012, 1,241 patients with chronic hepatitis B (CHB) were recruited. 
All patients underwent transient elastography at enrollment. The median age of the 
study population (840 males, 401 females) was 49 years. The median PAGE-B, LSM-
HCC, and mREACH-B values were 10, 10, and 8, respectively. Among patients without 
cirrhosis (n = 940, 75.7%), the median REACH-B value was 9. During the follow-up 
period (median 77.4 months), 66 (5.3%) and 83 (6.7%) patients developed HCC and 
liver-related events (LRE), respectively. Higher liver stiffness (LS) independently 
predicted HCC (hazard ratio [HR] = 1.047) and LRE development (HR = 1.047) (all 
P < 0.05). The mREACH-B significantly predicted HCC (AUC = 0.824 at 3-year and 
0.750 at 5-year) and LRE development (AUC = 0.782 at 3-year and 0.739 at 5-year) 
(all P < 0.001) and it performed similarly or significantly better than the PAGE-B and 
LSM-HCC (AUC = 0.715-0.809 at 3-year and 0.719-0.742 at 5-year for HCC; AUC = 
0.704-0.777 at 3-year and 0.721-0.735 at 5-year for LRE). Among patients without 
cirrhosis, mREACH-B predicted HCC (AUC = 0.803 vs. 0.654-0.816 at 3-year and 
0.684 vs. 0.639-0.738 at 5-year) and LRE development (AUC = 0.734 vs. 0.619-0.789 
at 3-year and 0.674 vs. 0.626-0.729 at 5-year) similarly to PAGE-B, REACH-B, and 
LSM-HCC. mREACH-B appropriately predicted HCC and LRE development in patients 
with CHB and showed similar or superior accuracy to those of PAGE-B, REACH-B, and 
LSM-HCC.
INTRODUCTION
Chronic hepatitis B (CHB) virus infection is a leading 
cause of liver cirrhosis and hepatocellular carcinoma (HCC), 
especially in Asian countries, where chronic hepatitis B virus 
(HBV) infection is endemic [1, 2]. If HCC is diagnosed at 
an early stage during surveillance, the chance of a ‘cure’ 
and corresponding favorable long-term outcomes can be 
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expected. Thus, risk stratification and the early detection of 
HCC are of great importance in patients with CHB.
To date, several risk prediction models including 
the REACH-B and PAGE-B models showing acceptable 
accuracy have been proposed [3]. Of these, the 
REACH-B model, which includes gender, age, alanine 
aminotransferase (ALT) level, hepatitis B e antigen 
(HBeAg) status, and HBV DNA level as variables, was 
proposed from an Asian multi-center study [3]. However, 
because REACH-B was established from the cohort of 
CHB patients without cirrhosis, it is not applicable to the 
whole spectrum of patients with CHB, such as those with 
cirrhosis, who are at higher risk of HCC development and 
may benefit most from risk stratification. In addition, the 
prognostic accuracy of the PAGE-B model, which was 
established from Caucasian subjects with CHB [4], has 
not fully validated yet in Asian subjects.
Recently, based on the concept that detailed 
stratification according to fibrotic burden can be more 
prognostic [5], several liver stiffness (LS)-based risk 
prediction models such as the modified REACH-B 
(mREACH-B) and LSM-HCC models have been 
proposed. Although the prognostic accuracy of 
mREACH-B [6], which was established from REACH-B 
model by incorporating LS, assessed using transient 
elastography (TE) instead of HBV DNA, has been 
confirmed in several studies [7, 8], its external validation 
has yet to be performed. In addition, LSM-HCC model 
was recently proposed [9]. However, further validation 
of its prognostic accuracy and the comparison with 
mREACH-B are still required. 
Thus, in this multi-center retrospective cohort 
study, we sought to validate the prognostic accuracy of 
mREACH-B in predicting the risk of HCC and liver-
related event (LRE) development in comparison with other 
risk prediction models, including PAGE-B, REACH-B, 
and LSM-HCC models, in patients with CHB.
MATERIALS AND METHODS
Patients
A total of 1,538 patients with CHB who underwent 
TE examinations at four tertiary institutions (Gangnam 
Severance Hospital, Dongsan Medical Center, Korea 
University Hospital, and Soonchunhyang University 
Bucheon Hospital) from 2006 to 2012 were recruited 
for this retrospective multi-center cohort study. CHB 
was defined as the persistent presence of the serum HBV 
surface antigen for > 6 months.
Exclusion criteria were as follows: 1) TE 
examination failure (valid shot = 0), 2) unreliable LS 
values, 3) HCC or LRE development < 6 months after 
enrollment, 4) current or previous history of HCC, 
decompensation, or liver transplantation, 5) Child-Pugh 
class B or C, 6) co-infection with hepatitis C or HIV, 
7) right-sided heart failure, 8) ascites or pregnancy, 
9) significant alcohol consumption (> 40 g/daily), 10) 
significant medical comorbidities, and 11) insufficient data 
for risk model calculation (Supplementary Figure 1).
The study conformed to the ethical guidelines 
of the 1975 Declaration of Helsinki and was approved 
by the institutional review board of each institute. The 
requirement for written informed consent was waived due 
to the retrospective nature of the study.
Follow-up 
Each patient was screened for HCC with 
ultrasonography at their initial visit. If no evidence of 
HCC was detected, patients were followed up with 
αfetoprotein and ultrasonography every 3 or 6 months for 
HCC surveillance. Antiviral therapy (AVT) was started 
according to the guidelines of the Korean Association for 
the Study of the Liver [10]. During surveillance, HCC 
was diagnosed based on the guidelines of the American 
Association for the Study of Liver Diseases [1].
Primary end-points
The primary aim of this study was to evaluate the 
predictive value of risk prediction models for assessing the 
risks of HCC and LRE development. To avoid statistical 
repetition, we selected the earliest of LREs as a major 
event if a given patient experienced different types of LRE 
at different times. LRE included the development of HCC, 
decompensation, liver transplantation, and liver-related 
death.
Assessment of liver stiffness using transient 
elastography
The LS value was assessed using TE (FibroScan; 
EchoSens, Paris, France). LS values measured by 
experienced technicians or nurses (> 500 examinations) 
were expressed in kilopascals (kPa). The detailed process 
for TE assessment has been described previously [11-
13]. The interquartile range (IQR) served as an index of 
the intrinsic variability in LS values and corresponded 
to the interval of LS results containing 50% of the valid 
measurements between the 25th and 75th percentiles. 
The median value of the successful measurements was 
regarded as representative of the LS value only if the IQR 
to median value ratio was < 30%. In addition, the LS value 
with at least 10 valid measurements and a success rate > 
60% was considered reliable. 
Selection of risk prediction models for 
comparison
First, the REACH-B model, from which 
mREACH-B was derived, was selected [14]. The 
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mREACH-B score substitutes the LS value for the HBV 
DNA level in the REACH-B model [6]. Additionally, 
another LS-based LSM-HCC model was selected to 
compare its prognostic accuracy with mREACH-B [9]. 
The LSM-HCC score was generated from the LS values, 
age, serum albumin level, and HBV DNA level. Finally, 
we selected a recently proposed prediction model from 
Caucasian patients with CHB receiving AVT [15], named 
PAGE-B, which has age, gender, and platelet count, as 
constituent variables, because only one previous study 
validated PAGE-B in Asian patients with CHB with no 
comparison with the accuracy of LS-based models [4]. 
The detailed calculation methods are summarized in 
Supplementary Table 1.
Statistical analysis
Data are expressed as medians with IQRs or as 
n (%), as appropriate. Student’s t-test (or the Mann-
Whitney test) and the χ2 test (or Fisher’s exact test) were 
used to compare the baseline characteristics of patients 
with and without liver cirrhosis at baseline, which was 
diagnosed based on ultrasonographic findings, including 
splenomegaly, blunt angle, and morphological changes 
(nodularity of liver surface, atrophy of the right lobe, 
hypertrophy of the left and caudate lobes, expansion of 
periportal spaces, and intrahepatic nodules). For subgroup 
analysis, high ALT level was defined as > 40 IU/mL. 
Additionally, baseline characteristics of patients who 
developed HCC or LRE and those who did not were 
compared. Patients were censored at the time of first 
presentation of HCC or LRE according to the selection 
of end-points or at the last follow-up. The annual and 
cumulative incidence rates of HCC were calculated using 
the Kaplan-Meier method. To identify independent risk 
factors for HCC development, univariate and subsequent 
multivariate Cox proportional hazard regression analyses 
were conducted. Hazard ratios (HRs) and corresponding 
95% confidence intervals (CIs) are presented. The 3-, 5-, 
and 7-year cumulative incidences of HCC were assessed 
by calculating area under the curves (AUCs). The AUCs 
of the risk prediction models were compared between 
pairs using the method of Delong et al. A P value < 0.05 
(two-tailed test) was considered to indicate statistical 
significance. All analyses were performed using the SPSS 
software (ver. 20.0; SPSS Inc., Chicago, IL, USA).
RESULTS
Baseline characteristics
After excluding 61 patients due to TE examination 
failure or unreliable LS values (drop-out rate due to 
TE, 4.0%), 1,477 patients with a reliable LS value for 
calculating risk prediction models were selected. Then, 
a further 236 patients were excluded according to our 
exclusion criteria. Finally, 1,241 patients with CHB were 
included in this retrospective multi-center cohort study 
(Supplementary Figure 1).
Baseline characteristics at enrollment are 
summarized in Table 1. The median age of the patients 
(840 males, 401 females) was 49 years. In total, 301 
(24.3%) patients had liver cirrhosis and 557 (44.9%) were 
receiving AVT at enrollment. The median LS value was 
3.9 kPa. Additionally, the median PAGE-B value was 10 
and those of the LS-based prediction models of LSM-HCC 
and mREACH-B were 10 and 8, respectively. Among 
patients without liver cirrhosis, the median REACH-B 
value was 9.
Comparison between patients with and without 
liver cirrhosis
When the study population was stratified into 
two groups, with and without liver cirrhosis (Table 1), 
age, the proportions of male gender, diabetes, and on-
going AVT, total bilirubin level, and LS value were 
significantly higher in patients with liver cirrhosis than in 
those without it, whereas serum albumin level, aspartate 
aminotransferase (AST) level, ALT level, the proportion 
of HBeAg positivity, HBV DNA level, and platelet count 
were significantly lower in patients with liver cirrhosis (all 
P < 0.05). PAGE-B, LSM-HCC, and mREACH-B values 
were significantly higher in patients with liver cirrhosis 
than in those without it (all P < 0.001).
HCC and LRE development
The median follow-up period from enrollment was 
77.4 (IQR 56.2–97.7) months. In total, 66 (5.3%) and 83 
(6.7%) patients developed HCC and LRE, respectively. 
For patients who developed LRE, HCC mostly comprised 
LRE (64, 77.1%), followed by decompensation 
(n = 17, 20.5%) and liver-related death (n = 2, 2.4%). The 
cumulative incidence rates at 3, 5, and 7 years were 2.4%, 
4.6%, and 6.3% for HCC development and 3.0%, 5.6%, 
and 7.7% for LRE development, respectively (Figure 1).
When the study population was stratified according 
to liver cirrhosis, patients with liver cirrhosis experienced 
HCC and LRE development more frequently (1.1%, 
2.6%, and 3.5% for HCC and 8.8%, 15.1%, and 20.6% 
for LRE, respectively) than those without it (0.7%, 2.0%, 
and 2.5% for HCC and 7.7%, 12.5%, and 17.8% for LRE, 
respectively; log-rank test, all P < 0.001; Supplementary 
Figure 2).
Comparisons between patients who developed 
HCC and LRE and those who did not
Characteristics of the 66 (5.3%) patients who 
developed HCC and the 1,174 (94.6%) patients who 
did not and the 83 (6.7%) patients who developed LRE 
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and the 1,158 (93.3%) patients who did not are shown 
in Table 2. The age and proportions of hypertension and 
liver cirrhosis, total bilirubin level, LS value, and the 
values of three prediction models (PAGE-B, LSM-HCC, 
and mREACH-B) were significantly higher in patients 
who developed HCC than in those who did not (all P 
< 0.05), whereas serum albumin level, ALT level, and 
platelet count were significantly lower in patients who 
developed HCC (all P < 0.05). Similar findings were 
noted between patients who developed LRE and those 
who did not.
Independent predictors of HCC and LRE 
development
Independent predictors of HCC and LRE 
development were evaluated (Table 3). Univariate 
analyses identified age, liver cirrhosis, total bilirubin, 
serum albumin, platelet count, and LS value as 
significant predictors of HCC development, whereas 
age, liver cirrhosis, serum albumin, platelet count, 
and LS value were selected as significant predictors 
of LRE development (all P < 0.05). According to 
a multivariate analysis, older age (HR = 1.065), 
liver cirrhosis (HR = 2.724), and higher LS value 
(HR = 1.047) were independently associated 
with an increased risk of HCC development (all 
P < 0.05), whereas older age (HR = 1.057), liver cirrhosis 
(HR = 2.299), lower platelet count (HR = 0.994), and 
higher LS value (HR = 1.047) were independently 
associated with an increased risk of LRE development 
(all P < 0.05).
Unadjusted hazard ratio of models in predicting 
HCC and LRE development
The unadjusted HRs obtained from the prediction 
models are shown in Table 4. PAGE-B, LSM-HCC, 
and mREACH-B were significantly predictive of HCC 
and LRE development (HR = 1.176–1.366 for HCC 
and 1.109–1.325 for LRE; all P < 0.001). In patients 
without liver cirrhosis, PAGE-B, REACH-B, LSM-
HCC, and mREACH-B were predictive of HCC and LRE 
development (HR=1.116–1.246 for HCC and 1.087–1.214 
for LRE; all P < 0.05), except for REACH-B in predicting 
LRE (P = 0.115). In patients with liver cirrhosis, PAGE-B, 
LSM-HCC, and mREACH-B were also predictive of HCC 
and LRE development (HR = 1.074–1.248 for HCC and 
1.067–1.218 for LRE; all P < 0.05) except PAGE-B in 
predicting HCC (P = 0.100).
Predictive accuracy of models in predicting HCC 
and LRE development
The performance of the risk prediction models in 
predicting HCC at 3, 5, and 7 years was calculated (Table 
5, Figure 2). The accuracy of REACH-B was calculated 
only for patients without liver cirrhosis.
In the entire study population, the mREACH-B 
score showed higher performance in predicting HCC 
than those of the PAGE-B and LSM-HCC at 3 years 
(AUC = 0.824 vs. 0.715 and 0.809, respectively), 5 years 
(AUC = 0.750 vs. 0.719 and 0.742, respectively), and 7 
years (AUC = 0.770 vs. 0.714 and 0.765, respectively). 
However, a statistically significant difference was seen 
Figure 1: Cumulative incidence rates of HCC and LRE (Kaplan-Meier plot). The cumulative incidence rates of HCC at 3, 
5, and 7 years were 2.4%, 4.6%, and 6.3%, respectively (A), whereas those of LRE were 3.0%, 5.6%, and 7.7%, respectively (B). HCC, 
hepatocellular carcinoma; LRE, liver-related event.
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only between mREACH-B and PAGE-B at 3 years (P = 
0.014). 
When patients with normal ALT were selected 
(n = 707, 57.0%) to exclude the overestimating influence 
of high ALT on LS-based prediction models, AUC values 
of mREACH-B and LSM-HCC were higher than those 
of PAGE-B (AUC = 0.823–0.730 for mREACH-B, 
0.793–0.740 for LSM-HCC vs. 0.734–0.699 for PAGE-B 
at 3–7 years), but the difference was not statistically 
significant (all P > 0.05). However, among patients with 
high ALT levels (n = 534, 43.0%), mREACH-B showed 
significantly higher AUC values than PAGE-B (0.826 vs. 
0.696 at 3 years, P = 0.004, and 0.818 vs. 0.736 at 7 
years, P = 0.049).
In the subgroup for patients without liver cirrhosis 
in whom REACH-B could be applied (n = 940, 75.7%), 
PAGE-B, LSM-HCC, and mREACH-B showed higher 
AUC values than REACH-B (AUC=0.738–0.693 for 
PAGE-B, 0.816–0.706 for LSM-HCC, and 0.803–0.684 
for mREACH-B vs. 0.654–0.639 for REACH-B), but the 
difference was not statistically significant (all P > 0.05). 
Similar findings were seen in patients with liver cirrhosis 
(n = 301, 24.3%).
When the performance of the risk prediction models 
in predicting LRE at 3, 5, and 7 years was calculated 
(Supplementary Table 2, Supplementary Figure 3), overall 
trends for the predictive accuracy of prediction models 
were similar to those of HCC prediction.
Predictive accuracy of models according to AVT 
status
When the patients with on-going AVT at enrollment 
were selected (n = 557), mREACH-B showed similar or 
higher AUC value than PAGE-B and LSM-HCC models at 
3 years (0.846 vs. 0.674 and 0.809). At 5 and 7 years, AUC 
values of mREACH-B and LSM-HCC were similar (0.778 
vs. 0.779 at 5 years; 0.788 vs. 0.789 at 7 years), but higher 
than those of PAGE-B model (0.688 at 5 years and 0.694 
at 7 years). In addition, when the patients without on-
Table 1: Baseline characteristics of the study population (n = 1,241)
Variables All
Liver cirrhosis
Without (940, 75.7%) With (301, 24.3%) P value
Demographic variables
  Age, years 49 (40–57) 47 (38–55) 54 (48–61) < 0.001
  Male gender 840 (67.7) 617 (65.6) 223 (74.1) 0.007 
  BMI, kg/m2 23.5 (21.5–25.4) 23.3 (21.4–25.4) 23.8 (22.0–25.5) 0.141 
  Diabetes 92 (7.4) 55 (5.9) 37 (12.3) 0.001 
  Hypertension 109 (8.8) 75 (8.0) 34 (11.3) 0.080 
  On-going AVT 557 (44.9) 393 (41.8) 164 (54.5) < 0.001
Laboratory variables
  Total bilirubin, mg/dL 0.8 (0.6–1.0) 0.8 (0.6–1.0) 0.9 (0.7–1.1) < 0.001
  Serum albumin, g/dL 4.4 (4.1–4.6) 4.4 (4.1–4.6) 4.3 (4.1–4.5) < 0.001
  AST, IU/L 32 (23–53) 30 (22–52) 36 (27–53) 0.004 
  ALT, IU/L 35 (22–71) 35 (21–79) 35 (24–56) < 0.001
  AFP, ng/mL 3.10 (2.10–5.00) 2.90 (2.00–4.50) 3.95 (2.55–7.00) 0.537 
  HBeAg positivity 562 (45.3) 452 (48.1) 110 (36.5) 0.001 
  HBV DNA, log10 IU/mL 3.9 (2.0–6.6) 4.0 (2.1–7.0) 3.6 (1.6–5.8) 0.001 
  Platelet count, 109/L 185 (142–228) 198 (161–237) 136 (101–179) < 0.001
Liver stiffness, kPa 3.9 (4.7–11.0) 6.1 (4.5–8.7) 11.9 (7.9–17.4) < 0.001
Risk prediction models
  PAGE-B 10 (8–15) 9 (7–14) 14 (10–16) < 0.001
  REACH-B - 9 (7–11) - -
  LSM-HCC 10 (5–18) 10 (0–15) 18 (10–24) < 0.001
  mREACH-B 8 (6–10) 7 (6–9) 10 (8–12) < 0.001
Variables are expressed as median (interquartile range) or n (%).
BMI, body mass index; AVT, antiviral therapy; AST, aspartate aminotransferase; ALT, alanine aminotransferase; AFP, alpha-
fetoprotein; HBeAg, hepatitis B e antigen; kPa, kilopascal.
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going AVT were analyzed (n = 684), mREACH-B showed 
similar or higher AUC values than those of PAGE-B and 
LSM-HCC models (0.764 vs. 0.741 and 0.716 at 3 years; 
0.735 vs. 0.734 and 0.735 at 5 years; 0.784 vs. 0.727 and 
0.741 at 7 years).
Risk stratification according to mREACH-B
We stratified the study population into four risk 
groups according to mREACH-B based on established cut-
off values (Table 6) [8]. The cumulative incidence rates of 
HCC and LRE development were significantly different in 
low-risk versus low-intermediate-risk groups and between 
high-intermediate-risk and high-risk groups (all P < 0.05, 
log-rank test), whereas they were statistically similar 
between low-intermediate-risk and high-intermediate 
risk groups (P = 0.270, log-rank test; Supplementary 
Figure 4). Similar trends were noted with regard to LRE 
development (Table 6, Supplementary Figure 4). However, 
when high- and low-intermediate risk groups were merged 
as an intermediate-risk group, there were significantly 
different rates of HCC and LRE development (data not 
shown).
DISCUSSION 
An accurate assessment of the risk of HCC and LRE 
development is important for establishing individualized 
strategies of follow-up, intervention, and management, 
because this ultimately enables the extension of overall 
survival in patients with CHB. To address this, several 
risk prediction models for patients with CHB have been 
proposed [6, 9, 14, 15]. In this study, we attempted to 
validate the prognostic accuracy of the mREACH-B model, 
Figure 2: Receiver operating characteristic curves of the PAGE-B, LSM-HCC, and mREACH-B scores for the prediction of HCC 
development at 3 (A), 5 (B), and 7 years (C) in the entire study population. HCC, hepatocellular carcinoma.
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which is a modified version of the REACH-B model, and 
found that the mREACH-B model significantly predicted 
the risk of HCC and LRE development in the whole study 
population (AUC ≥ 0.750 for HCC and ≥ 0.739 for LRE at 
3–7 years). Additionally, the mREACH-B model performed 
similarly or significantly better than the PAGE-B, 
REACH-B, and LSM-HCC models in our cohort.
Our study has several clinical implications. First, 
this study involved a large number of patients (n = 1,241) 
and a long follow-up period (median > 6 years and 
maximum around 10 years), which may have increased 
the statistical power and reliability. We attempted to obtain 
a larger number of patients who achieved our primary end-
points during this long-term follow-up period (n = 66, 
5.3% for HCC and n = 83, 6.7% for LRE). Additionally, 
this large sample size could facilitate stratification of 
the study population according to cirrhosis and ALT 
level. In the entire study population, the mREACH-B 
score showed significantly superior predictive value 
for HCC and LRE development at 3 years compared 
with that of PAGE-B (AUC = 0.824 vs. 0.715 for HCC 
and 0.782 vs. 0.704 for LRE, all P < 0.05), and similar 
predictive value to that of LSM-HCC at 3, 5, and 7 
years. When a subgroup without cirrhosis was selected 
to investigate the accuracy of REACH-B, we found that 
the accuracy of mREACH-B was higher than that of 
the original REACH-B model (AUC = 0.803–0.684 vs. 
0.639–0.654 for HCC and 0.734–0.674 vs. 0.626–0.600 
for LRE). However, the difference was not statistically 
significant, probably due to the relatively small sample 
size of the participants and events in this subgroup without 
cirrhosis. Beyond these results, that the LS value was 
selected as an independent predictor of HCC and LRE 
development (both HR = 1.047) and REACH-B did not 
show a significant unadjusted HR for predicting LRE 
may support the superiority of LS-based risk prediction 
models. Additionally, stratification according to ALT level 
revealed that the accuracy of mREACH-B was maintained 
at 3–7 years (AUC = 0.723–0.792 in normal ALT vs. 
0.786–0.756 in high ALT) and its similar or superior 
accuracy when compared to those of other models was 
also maintained, regardless of ALT level. In addition, in 
Table 2: Baseline characteristics of patients who developed HCC and LRE versus those who did not
Variables





(n = 1,174, 94.6%) (n = 66, 5.3%) (n = 1,158, 93.3%) (n = 83, 6.7%)
Demographic variables
  Age, years 49 (40–56) 58 (51–64) < 0.001 49 (39–56) 57 (50–64) < 0.001
  Male gender 789 (67.2) 50 (75.8) 0.176 780 (67.4) 60 (72.3) 0.396 
  Body mass index, kg/m2 23.4 (21.4–25.4) 24.2 (22.8–25.5) 0.917 23.4 (21.5–25.4) 23.8 (22.0–25.4) 0.684 
  Diabetes 85 (7.2) 7 (10.6) 0.329 83 (7.2) 9 (10.8) 0.198 
  Hypertension 93 (7.9) 16 (24.2) < 0.001 89 (7.7) 20 (24.1) < 0.001
  Liver cirrhosis 255 (21.7) 46 (69.7) < 0.001 246 (21.2) 55 (66.3) < 0.001
  On-going AVT 522 (44.5) 34 (51.5) 0.309 520 (44.9) 37 (44.6) 0.999 
Laboratory variables
  Total bilirubin, mg/dL 0.8 (0.6–1.0) 0.9 (0.6–1.2) 0.049 0.8 (0.6–1.0) 0.9 (0.6–1.1) 0.035 
  Serum albumin, g/dL 4.4 (4.1–4.6) 4.2 (4.0–4.5) 0.002 4.4 (4.1–4.6) 4.2 (4.0–4.5) 0.002 
  Aspartate aminotransferase, IU/L 31 (23–52) 45 (32–62) 0.146 31 (23–52) 44 (19–63) 0.211 
  Alanine aminotransferase, IU/L 35 (21–71) 40 (28–63) 0.001 35 (22–71) 40 (25–64) 0.001 
  Alpha-fetoprotein, ng/mL 3.10 (2.10–4.88) 4.70 (2.50–10.15) 0.749 3.10 (2.10–6.70) 4.10 (2.33–9.43) 0.704 
  HBeAg positivity 536 (45.7) 26 (39.4) 0.374 528 (45.6) 34 (41.0) 0.427 
  HBV DNA, log IU/mL 3.8 (2.0–6.7) 5.3 (2.3–6.5) 0.623 3.9 (2.1–6.7) 3.8 (1.7–6.4) 0.596 
  Platelet count, 109/L 190 (144–229) 125 (1034–170) < 0.001 190 (145–229) 124 (90–177) < 0.001
Liver stiffness, kPa 6.8 (4.8–10.5) 12.2 (8.4–21.2) < 0.001 6.8 (4.8–10.4) 12.0 (7.9–20.9) < 0.001
Risk prediction models
  PAGE-B 10 (7–15) 15 (11–16) < 0.001 10 (7–15) 15 (10–16) < 0.001
  LSM-HCC 10 (5–18) 19 (14–24) < 0.001 10 (5–18) 18 (10–24) < 0.001
  mREACH-B 8 (6–10) 11 (9–13) < 0.001 8 (6–10) 11 (9–13) < 0.001
Variables are expressed as median (interquartile range) or n (%).
HCC, hepatocellular carcinoma; LRE, liver-related event; AVT, antiviral therapy; HBeAg, hepatitis B e antigen; kPa, kilopascal.
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Table 3: Independent predictor of HCC and LRE development
Variables
Hepatocellular carcinoma Liver-related event
Univariate Multivariate Univariate Multivariate
P value Hazard ratio 95% CI P value P value
Hazard 
ratio 95% CI P value
Demographic variables
  Age, years < 0.001 1.065 1.038–1.093 < 0.001 < 0.001 1.057 1.034–1.081 <0.001
  Male gender 0.173 - - - 0.398 
  Body mass index, kg/m2 0.853 - - - 0.725 
  Diabetes 0.335 - - - 0.230 
  Liver cirrhosis < 0.001 2.724 1.495–4.965 0.001 < 0.001 2.299 1.362–3.881 0.002
  On-going AVT 0.335 - - - 0.798 
Laboratory variables
  Total bilirubin, mg/dL 0.021 1.369 0.768–2.437 0.287 0.052 
  Serum albumin, g/dL 0.001 1.054 0.484–2.295 0.895 < 0.001 1.135 0.567–2.271 0.720
  Aspartate aminotransferase, IU/L 0.582 - - - 0.999 
  Alanine aminotransferase, IU/L 0.163 - - - 0.140 
  Alpha-fetoprotein, ng/mL 0.733 - - - 0.650 
  HBeAg positivity 0.269 - - - 0.351 
  HBV DNA, log IU/mL 0.693 - - - 0.508 
  Platelet count, 109/L < 0.001 0.996 0.991–1.001 0.144 < 0.001 0.994 0.989–0.999 0.012
Liver stiffness, kPa < 0.001 1.047 1.018–1.077 0.002 < 0.001 1.047 1.021–1.074 < 0.001
HCC, hepatocellular carcinoma; LRE, liver-related event; CI, confidence interval; AVT, antiviral therapy; HBeAg, hepatitis B e antigen; kPa, kilopascal.
Table 4: Unadjusted hazard ratios of prediction models
Models
Hepatocellular carcinoma Liver-related event
Hazard ratio 95% CI P value Hazard ratio 95% CI P value
All
  PAGE-B 1.176 1.107–1.250 < 0.001 1.158 1.098–1.220 < 0.001
  REACH-B - - - - - -
  LSM-HCC 1.125 1.091–1.160 < 0.001 1.109 1.080–1.138 < 0.001
  mREACH-B 1.366 1.256–1.486 < 0.001 1.325 1.231–1.426 < 0.001
Without cirrhosis
  PAGE-B 1.174 1.057–1.303 0.003 1.104 1.017–1.198 0.018
  REACH-B 1.219 1.048–1.417 0.010 1.103 0.976–1.247 0.115
  LSM-HCC 1.116 1.057–1.178 < 0.001 1.087 1.039–1.137 < 0.001
  mREACH-B 1.246 1.074–1.445 0.004 1.214 1.071–1.376 0.002
With cirrhosis
  PAGE-B 1.069 0.987–1.158 0.100 1.090 1.011–1.176 0.026
  REACH-B - - - - - -
  LSM-HCC 1.074 1.033–1.117 < 0.001 1.067 1.030–1.105 < 0.001
  mREACH-B 1.248 1.113–1.399 < 0.001 1.218 1.101–1.349 < 0.001
CI, confidence interval.
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spite of well-known confounding influence of high ALT 
level on LS [16], the overall prognostic accuracy of LS-
based risk models was slightly higher in the subgroup 
with high ALT level than that in the subgroup with normal 
ALT. Although the exact reasons are unclear, the relatively 
low ALT level of our study population (median 35 IU/L) 
and the high proportion of patients with on-going AVT 
at enrollment (around 45%) might have attenuated the 
influence of high ALT level. Thus, the influence of a high 
ALT level on LS-based risk prediction models should be 
investigated further [17].
Second, the mREACH-B model showed statistically 
similar accuracy in predicting HCC and LRE development 
to the LSM-HCC model in the entire study population and 
various subgroups, although previous studies showed 
the superior accuracy of mREACH-B [7, 8]. Because 
LSM-HCC included HBV DNA level, with diminished 
importance due to AVT [5], and mREACH-B was 
established based on the empirical weight allocation on LS 
stratification, the accuracy of LS-based prediction models 
may be altered according to the proportion of patients with 
on-going AVT and the different weight allocation strategy 
of the mREACH-B model for patients with high fibrotic 
burden. Further studies seem required to compare the 
predictive accuracy of these two LS-based risk models.
Third, we could compare the accuracy of PAGE-B 
with those of LS-based models. Although the PAGE-B 
model was recently proposed for Caucasian patients with 
CHB receiving AVT [15], only one validation study is 
currently available [4]; it concluded that the accuracy 
of PAGE-B was similar to that of the CU-HCC and 
GAG-HCC models, but significantly higher than that 
of the REACH-B model. In our study, AUC values of 
PAGE-B were also higher than those of REACH-B in 
predicting HCC and LRE development, but lower than 
those of LS-based models, although the differences were 
not statistically significant. Although the reason for this 
remains unclear, it may be explained in part by the platelet 
count, which is an important variable in the PAGE-B 
model, but was not selected as an independent predictor of 
HCC development (P = 0.144). Additionally, because the 
PAGE-B model was established from a cohort with AVT, 
Table 5: Comparison of the prognostic accuracy of risk prediction models for HCC development
Study groups At 3 years At 5 years At 7 years
  Prediction models AUC 95% CI P value1 AUC 95% CI P value1 AUC 95% CI P value1
All (n = 1,241)
  PAGE-B 0.715** 0.644–0.787 0.014 0.719** 0.659–0.779 0.445 0.714** 0.661–0.766 0.111 
  REACH-B - - - - - - - - -
  LSM-HCC 0.809** 0.742–0.876 0.444 0.742** 0.677–0.809 0.639 0.765** 0.709–0.821 0.781 
  mREACH-B 0.824** 0.765–0.884 - 0.750** 0.689–0.811 - 0.770** 0.717–0.823 -
With normal ALT (n = 707)
  PAGE-B 0.734* 0.652–0.817 0.174 0.704** 0.630–0.778 0.541 0.699** 0.628–0.770 0.541 
  REACH-B - - - - - - - - -
  LSM-HCC 0.793** 0.652–0.884 0.312 0.742** 0.663–0.822 0.842 0.740** 0.665–0.816 0.687 
  mREACH-B 0.823** 0.740–0.906 - 0.737** 0.658–0.816 - 0.730** 0.654–0.807 -
With high ALT (n = 534)
  PAGE-B 0.696* 0.577–0.814 0.004 0.737** 0.638–0.836 0.359 0.736** 0.658–0.813 0.049 
  REACH-B - - - - - - - - -
  LSM-HCC 0.837** 0.744–0.929 0.658 0.766** 0.660–0.872 0.401 0.801** 0.723–0.879 0.447 
  mREACH-B 0.826** 0.744–0.907 - 0.786** 0.701–0.871 - 0.818** 0.755–0.880 -
Without cirrhosis (n = 940)
  PAGE-B 0.693 0.542–0.843 0.399 0.738** 0.648–0.829 0.535 0.721* 0.637–0.805 0.879 
  REACH-B 0.654 0.477–0.831 0.280 0.639 0.506–0.773 0.600 0.653* 0.535–0.772 0.221 
  LSM-HCC 0.816* 0.704–0.928 0.734 0.706* 0.577–0.836 0.556 0.725* 0.609–0.840 0.507 
  mREACH-B 0.803* 0.667–0.940 - 0.684* 0.564–0.804 - 0.691* 0.584–0.798 -
With cirrhosis (n = 301)
  PAGE-B 0.584 0.475–0.694 0.083 0.591 0.494–0.689 0.374 0.582 0.497–0.667 0.074 
  REACH-B - - - - - - - - -
  LSM-HCC 0.686* 0.574–0.798 0.643 0.630* 0.533–0.727 0.602 0.659* 0.575–0.743 0.483 
  mREACH-B 0.702* 0.598–0.805 - 0.644* 0.554–0.735 - 0.677** 0.598–0.755 -
1P value indicates the comparison between mREACH-B and other prediction models. AUC* and ** indicate P value of < 0.05 and < 0.001, respectively.
HCC, hepatocellular carcinoma; AUC, area under curve; CI, confidence interval; ALT, alanine aminotransferase.
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its direct application in our cohort with mixed AVT status 
might have lessened the accuracy of the PAGE-B model.
Fourth, we tested not only the accuracy of risk 
prediction models for HCC development, but also 
for the comprehensive end-point of LRE, and found 
that all prediction models significantly predicted LRE 
development, except the REACH-B model (P = 0.115). 
Although HCC represented most LRE (77.1%), the AUC 
values of prediction models became slightly lower when 
LRE was used as an end-point. Because the PAGE-B, 
REACH-B, and LSM-HCC models were established to 
predict HCC development, further validation studies on 
the applicability of the models in predicting LRE should 
be conducted.
We are aware of several other issues that should be 
taken into consideration. First, the study population was 
derived retrospectively from tertiary academic institutions, 
which might have resulted in the relatively high proportion 
of patients with liver cirrhosis (24.4%). In addition, our 
definition of chronic hepatitis B might include HBV 
carriers rather than active hepatitis. Thus, our findings 
should be validated in future prospective studies involving 
the full spectrum of HBV disease in a community-based 
setting. Second, in some subgroups, the accuracy of the 
mREACH-B model was higher than those of other risk 
models. However, because the overall accuracy of the 
mREACH-B model in the entire population was not so 
prominent, we could not strongly insist the prognostic 
superiority of the mREACH-B score. Further validation 
studies are warranted to resolve this issue. Third, although 
all the technicians and nurses in our multi-center study 
who performed TE had sufficient experience [18], inter-
institutional variability might have confounded our results. 
Additionally, the drop-out rates due to LS measurement 
failure or unreliable LS values (4.0%) were significantly 
lower than in a European study [19]. However, this failure 
rate seems similar to those of other Asian studies (from 
1.1% to 3.5%) [20], probably due to the lower body 
mass index (median 23.5 kg/m2) in our study. Moreover, 
during TE examinations, the skin capsular distance was 
not measured. Because this thickness can influence the 
detection of advanced fibrosis by TE [21], future studies 
should take this issue into considerations. Fourth, the 
risks of HCC and LRE development can change, because 
clinical and laboratory variables, such as fibrotic burden 
(liver stiffness and liver cirrhosis), ALT levels, HBeAg 
status, and HBV DNA levels, can change due to prolonged 
AVT, especially in this era of potent antiviral agents. 
Thus, our next multi-center study would investigate 
the impact of AVT on risk prediction models and the 
optimal cutoffs which might help to triage patients into 
different surveillance strategies. Finally, a reduction in 
LS value during AVT has been reported to be a favorable 
prognostic factor [22]. Thus, dynamic risk assessment 
using the risk prediction models is important. However, 
because we focused first on validating the accuracy 
of mREACH-B, in comparison with other prediction 
models, based on baseline characteristics, the clinical 
implication of dynamic changes in risk prediction models 
was not investigated in this study. Further well-designed 
studies with serial assessments of risk prediction models, 
which can provide more relevant clinical information and 
validate our results, should be performed.
In conclusion, the mREACH-B model appropriately 
predicted HCC and LRE development in patients with 
CHB and showed similar or superior accuracy to PAGE-B, 
REACH-B, and LSM-HCC. However, further validation 
studies are needed to investigate whether to incorporate 
mREACH-B into current surveillance strategies and its 
feasibility in dynamic assessments in patients with CHB.
Table 6: Cumulative incidence rates of HCC and LRE development according to previously known 
cut-off values with mREACH-B 
End-point
3 years (%) 5 years (%) 7 years (%) P value1
  Risk groups
Hepatocellular carcinoma
  Low-risk < 6 (n = 262, 21.2%) 0 0 0 0.005 
  Low-intermediate-risk 6–7 (n = 306, 24.6%) 0.3 3.2 3.7 0.270 
  High-intermediate-risk 8–10 (n = 394, 31.7%) 2.1 3.9 4.7 < 0.001
  High-risk >10 (n = 279, 22.5%) 7.2 11.6 17 -
Liver-related event
  Low-risk < 6 (n = 262, 21.2%) 0.4 0.4 0.4 0.005 
  Low-intermediate-risk 6–7 (n = 306, 24.6%) 1.0 3.9 4.4 0.152 
  High-intermediate-risk 8–10 (n = 394, 31.7%) 3.6 4.8 7.2 < 0.001
  High-risk >10 (n = 279, 22.5%) 8.0 13.6 19.8 -
P value1 indicates the comparison with adjacent higher risk group.
HCC, hepatocellular carcinoma; LRE, liver-related event.
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